Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence

SIMPLE SUMMARY: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are widely used to treat metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Despite the effectiveness of CDK4/6 inhibitors, acquired resistance occurs in almost all cases. Strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Kamal, Park, Nahee, Park, Kyung-Soon, Hur, Jin, Cho, Yong Bin, Kang, Minsil, An, Hee-Jung, Kim, Sewha, Hwang, Sohyun, Moon, Yong Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768442/
https://www.ncbi.nlm.nih.gov/pubmed/33260316
http://dx.doi.org/10.3390/cancers12123566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768442/
https://www.ncbi.nlm.nih.gov/pubmed/33260316
http://dx.doi.org/10.3390/cancers12123566

Ejemplares similares